secwatch.observer — SEC 8-K summary
======================================

Issuer:     CinCor Pharma, Inc. (—)
CIK:        0001868734
Form:       8-K
Filed at:   2023-02-24T23:59:59+00:00
Accession:  0001193125-23-047746
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 2.01, 5.03, 3.01, 3.03, 5.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AstraZeneca completes acquisition of CinCor Pharma for $26/share plus $10 CVR; total ~$1.8B
--------------------------------------------------------------------------------

- AstraZeneca subsidiary acquired all outstanding CinCor shares for $26.00 cash per share plus one CVR worth up to $10.00 per share upon milestone.
- Total transaction value approximately $1.8 billion; 86.3% of shares tendered in offer.
- CinCor becomes wholly owned subsidiary of AstraZeneca; stock to be delisted from Nasdaq.
- All CinCor directors resigned; replaced by AstraZeneca appointees David E. White and Kevin Durning.
- Certificate of incorporation and bylaws amended and restated effective at merger close.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1868734/000119312523047746/0001193125-23-047746-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1868734/000119312523047746/d465819d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-047746

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer